KRAS and non-small cell lung carcinoma: Fancelli et al. conducted a retrospective analysis showing that single-agent chemotherapy had limited efficacy in the KRAS-mutant NSCLC population, while single-agent ICI or ICI plus chemotherapy could benefit this population, which was not related to PD-L1 overexpression [22].